NCT05077124 Safe and Timely Antithrombotic Removal (STAR) Registry
| NCT ID | NCT05077124 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CytoSorbents, Inc |
| Condition | Hemorrhage, Surgical |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-09-30 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2021-09-30 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.
Eligibility Criteria
Inclusion Criteria: * CytoSorb utilization for antithrombotic removal * Informed consent for prospective registry participation Exclusion Criteria: • Use of CytoSorb for purpose other than antithrombotic removal
Contact & Investigator
Michael Schmoeckel, Prof, MD
PRINCIPAL INVESTIGATOR
LMU Klinikum Großhadern
Frequently Asked Questions
Who can join the NCT05077124 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hemorrhage, Surgical. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05077124 currently recruiting?
Yes, NCT05077124 is actively recruiting participants. Contact the research team at star@cytosorbents.com for enrollment information.
Where is the NCT05077124 trial being conducted?
This trial is being conducted at Graz, Austria, Innsbruck, Austria, Klagenfurt, Austria, Vienna, Austria and 11 additional locations.
Who is sponsoring the NCT05077124 clinical trial?
NCT05077124 is sponsored by CytoSorbents, Inc. The principal investigator is Michael Schmoeckel, Prof, MD at LMU Klinikum Großhadern. The trial plans to enroll 1,000 participants.